Evidence map›Paper›PMID 31776380›Full record

ArticleScientific reports2019

Cromolyn sodium delays disease onset and is neuroprotective in the SOD1

Eric J Granucci, Ana Griciuc, Kaly A Mueller, Alexandra N Mills, Hoang Le, Amanda M Dios, Danielle McGinty, Joao Pereira, David Elmaleh, James D Berry and 4 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04428775 (A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis), which is not on this map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04428775 phase2terminatednot on this mapstarted 2020, after this paper: background citation

A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS)

TypeinterventionalSponsorAZTherapies, Inc.Ran2020 to 2021Enrolled12ConditionsAmyotrophic Lateral SclerosisArmsALZT-OP1a (cromolyn)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Neural cell state modulation bybioRxiv : the preprint server for biology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Senolytics: A Novel Strategy for Neuroprotection in ALS?International journal of molecular sciences · 2021
    Review
  8. NADBiomedicines · 2021
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Eric J GranucciHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.
Ana GriciucGenetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.
Kaly A MuellerHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.
Alexandra N MillsHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.
Hoang LeGenetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.ORCID http://orcid.org/0000-0001-8427-3230
Amanda M DiosHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.
Danielle McGintyGenetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.
Joao PereiraHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.
David ElmalehAZTherapies, Boston, MA, USA.
James D BerryHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.
Sabrina PaganoniHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.
Merit E CudkowiczHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA.
Rudolph E TanziGenetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.ORCID http://orcid.org/0000-0002-7032-1454
Ghazaleh Sadri-VakiliHealey Center for ALS at MassGeneral Hospital, Massachusetts General Hospital, Boston, MA, USA. gsadrivakili@mgh.harvard.edu.
Massachusetts General Hospital · USAZTherapies (United States) · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence suggests that neuroinflammatory processes are implicated in the initiation and progression of amyotrophic lateral sclerosis (ALS). Previous reports have demonstrated an increase in microgliosis and astrogliosis in the lumbar spinal cord of SOD1

Indexed as

Amyotrophic Lateral SclerosisAnimalsAnti-Inflammatory AgentsCromolyn SodiumCytokinesFemaleMaleMiceMice, Inbred C57BLMotor NeuronsNeuromuscular JunctionNeuroprotective AgentsSpinal CordSuperoxide Dismutase-1Anti-Inflammatory AgentsCromolyn SodiumCytokinesNeuroprotective AgentsSod1 protein, mouseSuperoxide Dismutase-1

Identifiers

PMID31776380
PMCPMC6881366
OpenAlexW2989970624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.